Multi-Omics Integrated Analysis: Technologies, Methods, and Applications

Multi-omics integrated analysis is a systems biology approach that combines data from genomics, transcriptomics, proteomics, metabolomics, and microbiomics to construct a comprehensive molecular picture of biological systems. This technical article outlines the analytical principles, sample requirements, testing items, integrated methods, and application scenarios of multi-omics joint analysis, providing a practical reference for researchers in biomedical research, drug development, agriculture, and precision medicine.

Technical Overview

Multi-omics integrated analysis refers to the coordinated measurement and joint interpretation of two or more molecular data layers derived from the same biological system. Because each omics layer captures only one dimension of biological complexity, such as DNA variation, RNA expression, protein abundance, or metabolite concentration, single-omics studies often fail to explain causal relationships between genotype and phenotype. By integrating multiple layers, researchers can map molecular events along the central dogma pathway, from genetic variation to regulatory changes, downstream protein function, and final metabolic output.

A typical integrated analysis includes experimental design, synchronized multi-layer data acquisition, quality control, data normalization, statistical integration, and biological interpretation. Integration strategies are generally classified into three categories: unsupervised multivariate methods that identify latent factors shared across omics layers, correlation and network-based methods that link molecular features between layers, and pathway- or knowledge-driven methods that project multi-layer data onto curated biological pathways. Common analytical frameworks include multi-omics factor analysis, sparse canonical correlation analysis, multi-block dimension reduction, weighted gene co-expression network analysis, and machine learning models such as random forest and graph neural networks trained on combined feature matrices.

Quality assurance is critical in multi-omics projects because batch effects between platforms can obscure genuine biological signals. Reputable service providers operate under ISO/IEC 17025 quality management systems, apply randomized experimental designs, include internal standards and reference materials in mass spectrometry runs, and follow internationally recognized reporting guidelines for sequencing and proteomics data. Biological samples used for integration should ideally be split from the same specimen and preserved under standardized biobanking conditions consistent with ISO 20387 requirements.

Testing Samples

Animal and Human Tissues

Fresh frozen tissue from liver, brain, heart, tumor, or other organs can be used for simultaneous extraction of DNA, RNA, protein, and metabolites. Samples should be snap-frozen in liquid nitrogen within 30 minutes of collection and stored at -80 degrees Celsius. Tumor samples should be matched with adjacent normal tissue where possible, and pathological confirmation with tumor content above 70 percent is recommended for sequencing-based layers.

Blood and Body Fluids

Peripheral blood supports genomic DNA from leukocytes, transcriptomics from PBMCs, proteomics and metabolomics from plasma or serum, and circulating biomarker analysis. EDTA tubes are preferred for DNA and RNA, while heparin-free plasma is preferred for metabolomics to avoid ion suppression in mass spectrometry. Cerebrospinal fluid, urine, and saliva are also accepted for targeted multi-omics studies.

Cells and Cultured Models

Cell lines, primary cells, and organoids provide highly controlled material for matched multi-omics profiling. Recommended input is approximately 1 to 5 million cells per omics layer, collected at the same passage and time point to ensure consistency across data layers.

Plant Tissues

Leaves, roots, seeds, and fruits can be profiled for genome, transcriptome, proteome, and metabolome integration in breeding and stress-response studies. Samples should be harvested at defined developmental stages, flash-frozen immediately, and protected from secondary metabolite degradation.

Fecal and Microbiome Samples

Fecal specimens support 16S rRNA gene sequencing, metagenomics, metatranscriptomics, and combined host-microbe integration studies. Samples should be frozen within 2 hours of collection or preserved with stabilizing reagents approved for nucleic acid integrity.

Testing Items

Integrated analysis projects typically combine two or more of the following testing modules, each delivering both standalone results and cross-layer integration outputs.

• Genomics layer: whole-genome resequencing, whole-exome sequencing, SNP genotyping, structural variation detection, and copy number analysis.
• Epigenomics layer: whole-genome bisulfite sequencing, methylation arrays, chromatin immunoprecipitation sequencing, and ATAC sequencing for open chromatin mapping.
• Transcriptomics layer: bulk RNA sequencing, full-length transcript sequencing, small RNA sequencing, and single-cell or spatial transcriptomics for high-resolution expression profiling.
• Proteomics layer: label-free quantitative proteomics, TMT multiplexed quantification, DIA-based proteomics, phosphoproteomics, and acetylomics.
• Metabolomics layer: untargeted metabolomics by LC-MS/MS, lipidomics, targeted quantification of amino acids, organic acids, bile acids, and short-chain fatty acids, and volatile compound profiling by GC-MS.
• Microbiomics layer: 16S rRNA gene sequencing, shotgun metagenomics, and functional microbiome annotation.
• Integration deliverables: cross-omics correlation matrices, differentially expressed feature intersection, multi-omics factor scores, co-expression network modules, joint pathway enrichment, biomarker panels, and causal regulatory hypothesis models.

Testing Methods

The analytical workflow proceeds through synchronized wet-lab and dry-lab stages. In the laboratory phase, matched aliquots from each specimen undergo nucleic acid extraction with quality verification by fluorometric quantification and integrity assessment, protein digestion with trypsin, and metabolite extraction with methanol-based solvent systems. Sequencing libraries are constructed and sequenced on high-throughput short-read platforms or long-read platforms as required by the project, while proteomic and metabolomic measurements are performed on UHPLC coupled to high-resolution tandem mass spectrometry.

In the bioinformatics phase, raw data pass platform-specific quality control, trimming, alignment or spectral matching, and quantitative matrix generation. Key processing steps include sequencing depth normalization, transformation of abundance data, missing value imputation, and batch effect correction using methods such as ComBat or RUV-based approaches. Statistical integration then applies algorithms selected according to study design: O2PLS and multi-factor analysis for exploratory two-table integration, sparse CCA and DIABLO frameworks for supervised biomarker selection, MOFA for unsupervised latent factor extraction, and WGCNA for module-level correlation between gene networks and metabolic traits.

Integrated results are mapped onto curated databases including KEGG, Reactome, Gene Ontology, HMDB, and STRING to convert statistical patterns into biological mechanisms. All candidate findings should be validated with orthogonal methods, including qRT-PCR for transcripts, parallel reaction monitoring or ELISA for proteins, and targeted LC-MS/MS for metabolites. Accredited third-party laboratories deliver raw sequencing data, mass spectrometry files, processed matrices, analysis code, and a comprehensive integration report with publication-quality figures.

Applications

Multi-omics integration is applied across life science research and industrial development wherever mechanism-oriented molecular insight is required.

• Disease mechanism research: identifying deregulated pathways that connect genetic susceptibility, epigenetic modification, gene expression, and metabolic reprogramming in cancer, metabolic disease, neurodegeneration, and autoimmune conditions.
• Biomarker discovery and validation: constructing multi-panel diagnostic, prognostic, and predictive biomarker models with improved sensitivity and specificity compared with single-molecule markers.
• Drug development: target identification through convergent evidence across omics layers, pharmacodynamic biomarker definition, and mechanism-based toxicity evaluation in preclinical studies.
• Precision medicine: patient stratification based on integrated molecular subtyping and support for individualized therapy selection in oncology and rare disease diagnostics.
• Agriculture and crop science: linking genotype to agronomic traits through combined genomic, transcriptomic, and metabolomic profiling in breeding programs and stress-tolerance research.
• Microbiome and host interaction studies: characterizing microbial community structure together with host immune, transcriptomic, and metabolic responses in nutrition and gastrointestinal research.
• Environmental and food safety toxicology: assessing exposure effects through combined transcriptomic and metabolomic signatures in ecotoxicology and contaminant risk assessment.

FAQ

What is multi-omics integrated analysis?

Multi-omics integrated analysis is the combined measurement and joint statistical interpretation of multiple molecular data types, such as genome, transcriptome, proteome, and metabolome, from matched biological samples. The goal is to reveal coordinated molecular changes and causal relationships that cannot be detected by any single omics technology alone.

Which combinations of omics layers are most commonly used?

Frequently selected combinations include transcriptome plus metabolome for pathway mechanism studies, genome plus transcriptome for expression quantitative trait locus analysis, proteome plus metabolome for functional phenotype studies, and 16S sequencing plus metabolome for host-microbiome interaction research. The optimal combination depends on the biological question and available sample material.

How many biological replicates are recommended?

A minimum of six biological replicates per group is recommended for two-layer integration, while eight to ten or more replicates per group are advisable when three or more layers are combined or when advanced multivariate models such as DIABLO are applied. Case-control and time-course designs may require additional replicates to achieve adequate statistical power.

Can different omics layers be measured from the same sample?

Yes, and this is strongly preferred. Simultaneous extraction kits allow DNA, RNA, protein, and metabolites to be recovered from a single pulverized tissue specimen, which minimizes biological variation between data layers. When separate aliquots must be used, they should be collected at the same time point and processed under identical conditions.

How are batch effects between different platforms handled?

Batch effects are controlled through randomized sample processing, balanced group distribution across sequencing lanes and mass spectrometry batches, inclusion of pooled quality control samples, and computational correction methods such as ComBat, RUV, and probabilistic latent factor modeling applied before integration.

What deliverables are provided at project completion?

Standard deliverables include raw sequencing data, mass spectrometry raw files, cleaned quantitative matrices for each omics layer, statistical analysis results, cross-omics correlation networks, pathway enrichment maps, executable analysis scripts, and a detailed integration report containing figure files suitable for publication.

How long does a typical integrated project take?

Laboratory measurement generally requires 4 to 8 weeks depending on the number of omics layers and sample count, followed by 2 to 4 weeks for integrated bioinformatics analysis and reporting. Projects involving method development, large cohorts, or validation experiments may require extended timelines, which should be defined in the project plan.

Can existing data from previous studies be integrated?

Yes. Publicly available or previously generated datasets can be integrated with newly generated data, provided that metadata are complete, sample matching is possible, and platform differences are addressed through appropriate normalization and batch correction strategies during analysis.